VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Akero Therapeutics, Inc. (AKRO) Total Return Calculator with Dividends Reinvested

Akero Therapeutics, Inc.

Popular:

The total return for Akero Therapeutics, Inc. (AKRO) stock is +30.06% over the past 12 months. The 5-year total return is +107.24%, meaning $10,000 invested in AKRO stock 5 years ago would be worth $20,724 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in AKRO 1 year ago, it would be worth $12,772 today — you'd have gained $2,772.

With Dividends Reinvested$12,772+27.72%

Price Only (No DRIP)$12,772+27.72%

Period2025-05-07 → 2025-12-09

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in AKRO

1Y$13,006+$3,006 (+30.1%)30.1% CAGR

3Y$12,006+$2,006 (+20.1%)6.3% CAGR

5Y$20,724+$10,724 (+107.2%)15.7% CAGR

10Y$29,831+$19,831 (+198.3%)11.5% CAGR

15Y$29,831+$19,831 (+198.3%)7.6% CAGR

20Y$29,831+$19,831 (+198.3%)5.6% CAGR

30Y$29,831+$19,831 (+198.3%)3.7% CAGR

Akero Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading AKRO total return...

As of 2026-05-06

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
1Y	+30.06%	30.06%	+30.06%	—	$13,006
3Y	+20.06%	6.28%	+20.06%	—	$12,006
5Y	+107.24%	15.69%	+107.24%	—	$20,724
10Y	+198.31%	11.55%	+198.31%	—	$29,831
15Y	+198.31%	7.56%	+198.31%	—	$29,831
20Y	+198.31%	5.62%	+198.31%	—	$29,831
30Y	+198.31%	3.71%	+198.31%	—	$29,831

Risk & Highlights

Best Year+152.53%2022

Worst Year-52.82%2023

Max Drawdown-25.05%2025-06-26 → 2025-09-17

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2025	+94.62%	+94.62%	—	+16.64%	+78.0pp
2024	+18.48%	+18.48%	—	+24.00%	-5.5pp
2023	-52.82%	-52.82%	—	+24.81%	-77.6pp
2022	+152.53%	+152.53%	—	-19.95%	+172.5pp
2021	-14.79%	-14.79%	—	+28.79%	-43.6pp

AKRO underperformed the S&P 500 by 1.27pp over the past year (+30.06% vs +31.32%).

Loading summary...

AKRO Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
AKROAkero Therapeutics, Inc.	$4.5B	—	—	+30.1%	—	+20.1%	+107.2%	+198.3%
MDGLMadrigal Pharmaceuticals, Inc.	$12.4B	+1.1%	-9.1%	+82.9%	—	+74.7%	+326.0%	+3755.2%
HALOHalozyme Therapeutics, Inc.	$7.8B	+5.2%	-5.6%	+11.7%	—	+119.1%	+39.1%	+598.4%
ELVNEnliven Therapeutics, Inc.	$2.4B	+5.8%	+165.1%	+109.2%	—	+115.3%	+44.9%	-31.3%
NVCRNovoCure Limited	$1.9B	+56.4%	+25.7%	+1.0%	—	-76.2%	-91.5%	+31.0%
GPCRStructure Therapeutics Inc.	$2.4B	-21.1%	-40.0%	+61.2%	—	+70.2%	+57.1%	+57.1%
TERNTerns Pharmaceuticals, Inc.	$4.6B	+0.4%	+32.1%	+1659.7%	—	+302.8%	+229.8%	+188.0%
VKTXViking Therapeutics, Inc.	$3.7B	-4.9%	-8.9%	+19.5%	—	+41.2%	+459.4%	+2503.2%
ALDXAldeyra Therapeutics, Inc.	$105M	+14.5%	-62.7%	-17.1%	—	-83.7%	-85.6%	-71.9%
CGEMCullinan Therapeutics, Inc.	$903M	+0.5%	+48.1%	+91.0%	—	+57.6%	-48.3%	-49.9%
ARWRArrowhead Pharmaceuticals, Inc.	$11.1B	+29.5%	+16.7%	+505.0%	—	+95.6%	+20.5%	+1315.7%

Compare:AKRO vs MDGL AKRO vs HALO AKRO vs ELVN AKRO vs MDGL vs HALO

About AKRO Dividend Returns

Akero Therapeutics, Inc. (AKRO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of AKRO over the past year?

Akero Therapeutics, Inc. (AKRO) delivered a return of 30.06% over the past year. Since AKRO does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in AKRO be worth today?

A $10,000 investment in Akero Therapeutics, Inc. one year ago would be worth $13,006 today, representing a gain of $3,006.

Q3Does AKRO pay dividends?

Akero Therapeutics, Inc. (AKRO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For AKRO, the total return equals the price-only return.

Q4Did AKRO beat the S&P 500?

No, Akero Therapeutics, Inc. (AKRO) underperformed the S&P 500 by 1.27 percentage points over the past year. AKRO delivered a total return of 30.06%, compared to the S&P 500's 31.32%. This means a passive S&P 500 index fund outperformed AKRO by 1.27pp during this period.

Q5What is AKRO's worst drawdown?

Akero Therapeutics, Inc. (AKRO) experienced a maximum drawdown of -25.05% over the past year, declining from its peak on 2025-06-26 to its trough on 2025-09-17. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is AKRO's long-term total return over 10, 20, or 30 years?

Here are Akero Therapeutics, Inc. (AKRO)'s long-term returns with dividends reinvested. Over 10 years, the total return is 198.3% (11.5% CAGR) — $10,000 would have grown to $29,831. Over 20 years: 198.3% total return (5.6% CAGR) — $10,000 → $29,831. Over 30 years: 198.3% total return (3.7% CAGR) — $10,000 → $29,831. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was AKRO's best and worst year?

Akero Therapeutics, Inc.'s best calendar year was 2022 with a total return of 152.5%. Its worst year was 2023 with a total return of -52.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 205.4 percentage points.